Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, 2 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

Do β-blockers pose more harm than good in decompensated cirrhosis?

26 Sep 2020

In patients with decompensated cirrhosis, β-blockers trigger a stronger systemic haemodynamic response and exert a weaker portal pressure-lowering effect, a recent study has found.

Of the 403 patients included, 190 and 213 had decompensated and compensated cirrhosis, respectively. Baseline active alcohol consumption was higher in decompensated patients, as was alcohol-related cirrhosis. Liver function, platelet count, and portal flow velocity were also worse in decompensated cirrhosis, and liver stiffness was greater.

Portal hypertension was more severe in decompensated patients at baseline, and they had a more developed hyperdynamic circulatory state.

Under treatment with β-blockers, portal pressure decrease was lower in decompensated patients (10±18 percent vs 15±12 percent; p<0.05), while reductions in heart rate (p<0.001) and cardiac output (p<0.01) were greater.

The probability of mortality was higher in decompensated, both at 3 years (14 percent vs 30 percent) and at 5 years (22 percent vs 41 percent; p<0.001 for both). Competing-risk regression analysis showed that cardiac output under β-blocker treatment was a good and independent predictor of mortality in decompensated patients (C-index, 0.74, 95 percent confidence interval, 0.66–0.83).

β-blockers are often used to reduce the risk of variceal bleeding in patients with cirrhosis,” researchers said. “Herein, we show that in patients with decompensated cirrhosis the potentially detrimental systemic effects of β-blockers are greater than in compensated patients, while the beneficial pressure lowering effects are reduced.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, 2 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.